Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001

Allyx Therapeutics announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics, and potential therapeutic response in patients with Parkinson’s disease. ALX-001 is a highly selective, first-in-class, synapse-targeted, disease-modifying oral therapy.